Sotsiou F C, Singhellakis P N, Nikou A D, Pappas A D, Vambouka C, Sklivagou N G, Ikkos D G
J Pathol. 1987 Apr;151(4):271-8. doi: 10.1002/path.1711510406.
Recent evidence suggests that cimetidine given pre-operatively in primary hyperparathyroidism (1 degree HPT) might cause structural changes in parathyroid glands, while its suppressive effects on the disease are disputable. To determine these possible changes we studied 38 patients with 1 degree HPT who underwent parathyroidectomy. In 14 of these (group I) cimetidine was given pre-operatively (1000 mg orally daily for 4 weeks). The remaining 24 patients (group II) did not take any drug. Parathyroid function was estimated by nephrogenous cAMP (NcAMP) and serum immunoreactive parathyroid hormone (iPTH) measurements. Histological examination of the parathyroids was made by conventional techniques. In group I at the end of cimetidine treatment, the only change observed was a small but significant (p less than 0.05) decrease of plasma calcium (-0.77 mg/dl). Histologically, the glands of group I--compared with those of group II--showed the following findings: increased gland mass: mean increase 1050 mg (adenomas) and 700 mg (hyperplasias); central oedema in all the cases of group I only; increased (about 50 per cent) cellular size and intranuclear 'inclusions' in 10 out of 14 cases of group I only. It is concluded that treatment with cimetidine in 1 degree HPT is followed by histopathologic alterations leading to increased size of the diseased parathyroids.
近期证据表明,原发性甲状旁腺功能亢进症(1°HPT)术前给予西咪替丁可能会导致甲状旁腺结构改变,但其对该疾病的抑制作用存在争议。为确定这些可能的变化,我们研究了38例接受甲状旁腺切除术的1°HPT患者。其中14例(I组)术前给予西咪替丁(每日口服1000mg,共4周)。其余24例患者(II组)未服用任何药物。通过测定肾源性环磷酸腺苷(NcAMP)和血清免疫反应性甲状旁腺激素(iPTH)评估甲状旁腺功能。采用传统技术对甲状旁腺进行组织学检查。I组在西咪替丁治疗结束时,观察到的唯一变化是血浆钙小幅但显著下降(p<0.05)(-0.77mg/dl)。组织学上,与II组相比,I组腺体有以下表现:腺体质量增加:腺瘤平均增加1050mg,增生平均增加700mg;仅I组所有病例均出现中央水肿;仅I组14例中有10例细胞大小增加(约50%)且核内有“包涵体”。结论是,1°HPT患者接受西咪替丁治疗后会出现组织病理学改变,导致患病甲状旁腺增大。